骨髓增殖性肿瘤与内脏静脉血栓形成:当代诊断和治疗策略
骨髓增殖性肿瘤是原发性内脏静脉血栓最常见的病因,在布加综合征或门静脉血栓患者中约占40%。由于门静脉高压或出血并发症会干扰血细胞计数升高和脾大等关键特征,诊断较为困难。JAK2V617F突变筛查应作为所有内脏静脉血栓患者诊断流程的起点,并需多学科方法明确骨髓增殖性肿瘤亚型、推荐附加检查及最佳治疗策略。
要点
- 骨髓增殖性肿瘤是原发性内脏静脉血栓最常见病因,约占布加综合征或门静脉血栓患者的40%。
- 所有内脏静脉血栓患者应以JAK2V617F突变筛查作为诊断起点。
- 骨髓活检仍是主要诊断标准,分子标志物在诊断和预后评估中作用日益增加。
核心结论
- 骨髓增殖性肿瘤是原发性内脏静脉血栓最常见病因,几乎所有布加综合征或门静脉血栓患者中约40%存在骨髓增殖性肿瘤。
- 所有内脏静脉血栓患者应筛查JAK2V617F突变,并需多学科方法明确骨髓增殖性肿瘤亚型、推荐附加检查及最佳治疗策略。
- 为内脏静脉血栓合并骨髓增殖性肿瘤患者提供特定专家诊疗路径对确定最佳管理以减少血液学和肝脏并发症风险至关重要。
研究设计与样本
- 综述,检索范围原文未报告。
主要发现
- 骨髓增殖性肿瘤是原发性内脏静脉血栓最常见病因,在布加综合征或门静脉血栓患者中约占40%。
- 内脏静脉血栓患者中,血细胞计数升高和脾大等关键特征可被门静脉高压或出血并发症干扰,使骨髓增殖性肿瘤诊断困难。
- 近年诊断工具改进,可更准确诊断和分类骨髓增殖性肿瘤。
- 骨髓活检发现仍是主要诊断标准,分子标志物在诊断和更准确估计预后方面作用日益增加。
关键数值与推荐
- 所有内脏静脉血栓患者诊断流程应以JAK2V617F突变筛查为起点。
- 骨髓活检为骨髓增殖性肿瘤主要诊断标准。
- 附加检查包括骨髓活检和使用靶向下一代测序寻找附加突变。
临床怎么用
- 所有内脏静脉血栓患者应筛查JAK2V617F突变作为诊断起点。
- 需多学科方法明确骨髓增殖性肿瘤亚型、推荐附加检查并建议最佳治疗策略。
- 应为内脏静脉血栓合并骨髓增殖性肿瘤患者提供特定专家诊疗路径以确定最佳管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myeloproliferative neoplasms (MPNs) are the most common etiologies of primary splanchnic vein thrombosis, present in almost forty percent of patients with Budd-Chiari syndrome or portal vein thrombosis. Diagnosis of MPNs can be difficult in these patients because key characteristics, such as elevated blood cell counts and splenomegaly, are confounded by portal hypertension or bleeding complications. In recent years, diagnostic tools have improved to provide more accurate diagnosis and classification of MPNs. Although bone marrow biopsy findings remain a major diagnostic criterion, molecular markers are playing an increasing role not only in diagnosis but also in better estimating prognosis. Therefore, though screening for JAK2V617F mutation should be the starting point of the diagnostic workup performed in all patients with splanchnic vein thrombosis, a multidisciplinary approach is needed to accurately diagnose the subtype of myeloproliferative neoplasm, recommend the useful additional tests (bone marrow biopsy, search for an additional mutation using targeted next-generation sequencing), and suggest the best treatment strategy. Indeed, providing a specific expert care pathway for patients with splanchnic vein thrombosis and underlying myeloproliferative neoplasm is crucial to determine the optimal management to reduce the risk of both hematological and hepatic complications.
引用
- Kiladjian JJ, Cassinat B. Myeloproliferative neoplasms and splanchnic vein thrombosis: Contemporary diagnostic and therapeutic strategies. Am J Hematol. 2023. PMID: 36869873. doi:10.1002/ajh.26896
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。